title: Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
abstract: Renal cell carcinoma (RCC) is an angiogenesis-dependent and hypoxia-driven malignancy. As a result, there has been an increased interest in the use of antiangiogenic agents for the management of RCC in patients. However, the activity of tumor-vascular disrupting agents (tumor-VDA) has not been extensively examined against RCC. In this study, we investigated the therapeutic efficacy of the tumor-VDA ASA404 (DMXAA, 5,6-dimethylxanthenone-4-acetic acid, or vadimezan) in combination with the mTOR inhibitor everolimus (RAD001) against RCC. In vitro studies were carried out using human umbilical vein endothelial cells and in vivo studies using orthotopic RENCA tumors and immunohistochemical patient tumor-derived RCC xenografts. MRI was used to characterize the vascular response of orthotopic RENCA xenografts to combination treatment. Therapeutic efficacy was determined by tumor growth measurements and histopathologic evaluation. ASA404/everolimus combination resulted in enhanced inhibition of endothelial cell sprouting in the 3-dimensional spheroid assay. MRI of orthotopic RENCA xenografts revealed an early increase in permeability 4 hours posttreatment with ASA404, but not with everolimus. Twenty-four hours after treatment, a significant reduction in blood volume was observed with combination treatment. Correlative CD31/NG2 staining of tumor sections confirmed marked vascular damage following combination therapy. Histologic sections showed extensive necrosis and a reduction in the viable rim following combination treatment compared with VDA treatment alone. These results show the potential of combining tumor-VDAs with mTOR inhibitors in RCC. Further investigation into this novel combination strategy is warranted.
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, New York 14263, USA.
authors.forename: Leigh
authors.initials: L
authors.lastname: Ellis
authors.forename: Preeti
authors.initials: P
authors.lastname: Shah
authors.forename: Hans
authors.initials: H
authors.lastname: Hammers
authors.forename: Kristin
authors.initials: K
authors.lastname: Lehet
authors.forename: Paula
authors.initials: P
authors.lastname: Sotomayor
authors.forename: Gissou
authors.initials: G
authors.lastname: Azabdaftari
authors.forename: Mukund
authors.initials: M
authors.lastname: Seshadri
authors.forename: Roberto
authors.initials: R
authors.lastname: Pili
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000941:Antigens / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D000068338:Everolimus; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008279:Magnetic Resonance Imaging; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D011509:Proteoglycans / Q000378:metabolism; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D018874:Spheroids, Cellular / Q000187:drug effects / Q000378:metabolism; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D047368:Tumor Burden / Q000187:drug effects; D044004:Xanthones / Q000008:administration & dosage / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays / Q000379:methods; D000099216:Chondroitin Sulfate Proteoglycan 4
chemical_list: D020533:Angiogenesis Inhibitors; D000941:Antigens; D000068338:Everolimus; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D011509:Proteoglycans; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases; D044004:Xanthones; D000099216:Chondroitin Sulfate Proteoglycan 4; C066668:vadimezan
references.citation: Cancer Res. 1999 Feb 1;59(3):633-8
references.pmid: 9973211
references.citation: Nat Rev Cancer. 2005 Jun;5(6):423-35
references.pmid: 15928673
references.citation: Ther Clin Risk Manag. 2009 Oct;5(5):699-706
references.pmid: 19774211
references.citation: J Magn Reson Imaging. 2004 Jul;20(1):138-44
references.pmid: 15221819
references.citation: Expert Rev Anticancer Ther. 2009 Jun;9(6):785-93
references.pmid: 19496715
references.citation: Cancer Res. 2009 Oct 1;69(19):7524-8
references.pmid: 19738066
references.citation: Cancer Res. 1999 Jul 15;59(14):3304-7
references.pmid: 10416582
references.citation: Lancet Oncol. 2003 Mar;4(3):141-8
references.pmid: 12623359
references.citation: Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):770s-776s
references.pmid: 17255308
references.citation: Nat Med. 2006 Jan;12(1):122-7
references.pmid: 16341243
references.citation: Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1233-40
references.pmid: 15519796
references.citation: Cancer Chemother Pharmacol. 2003 Jan;51(1):43-52
references.pmid: 12497205
references.citation: Eur J Nucl Med Mol Imaging. 2010 Aug;37 Suppl 1:S164-82
references.pmid: 20461374
references.citation: Magn Reson Med. 1997 Feb;37(2):236-42
references.pmid: 9001148
references.citation: J Clin Oncol. 2011 Aug 1;29(22):2965-71
references.pmid: 21709202
references.citation: Anticancer Res. 2008 Jul-Aug;28(4B):2027-31
references.pmid: 18751370
references.citation: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4538-46
references.pmid: 17671140
references.citation: Clin Cancer Res. 2008 Feb 1;14(3):892-900
references.pmid: 18245553
references.citation: Clin Cancer Res. 2008 Jun 1;14(11):3589-97
references.pmid: 18519793
references.citation: Cancer. 2010 Apr 15;116(8):1859-71
references.pmid: 20166210
references.citation: N Engl J Med. 2007 Jan 11;356(2):185-7
references.pmid: 17215538
references.citation: Cancer. 2009 May 15;115(10 Suppl):2334-45
references.pmid: 19402070
references.citation: Br J Cancer. 2002 Jun 17;86(12):1937-42
references.pmid: 12085190
references.citation: Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1198-207
references.pmid: 18954713
references.citation: Curr Top Microbiol Immunol. 2010;347:279-96
references.pmid: 20535652
references.citation: Clin Cancer Res. 2009 Mar 1;15(5):1612-22
references.pmid: 19223496
references.citation: Nature. 2006 Aug 17;442(7104):779-85
references.pmid: 16915281
references.citation: Discov Med. 2010 Nov;10(54):394-405
references.pmid: 21122471
references.citation: Clin Cancer Res. 2005 Jun 1;11(11):4241-50
references.pmid: 15930363
references.citation: Br J Cancer. 2007 Jan 29;96(2):189-95
references.pmid: 17211479
references.citation: Br J Cancer. 2008 Dec 16;99(12):2006-12
references.pmid: 19078952
references.citation: J Pathol. 2010 Jun;221(2):125-38
references.pmid: 20225241
references.citation: J Clin Oncol. 2006 Jul 10;24(20):3293-8
references.pmid: 16829653
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: J Clin Oncol. 2008 Oct 1;26(28):4572-8
references.pmid: 18824708
references.citation: Cancer Res. 1999 Oct 1;59(19):4770-5
references.pmid: 10519381
references.citation: Cancer Res. 2011 Mar 1;71(5):1573-83
references.pmid: 21363918
references.citation: Cancer Lett. 2010 Oct 28;296(2):249-56
references.pmid: 20471160
references.citation: Mol Cancer Ther. 2010 Jun;9(6):1525-35
references.pmid: 20501804
references.citation: Lancet. 2008 Aug 9;372(9637):449-56
references.pmid: 18653228
references.citation: Lancet Oncol. 2011 Jul;12(7):673-80
references.pmid: 21664867
references.citation: Expert Rev Mol Diagn. 2009 Apr;9(3):231-41
references.pmid: 19379082
references.citation: Curr Cancer Drug Targets. 2008 Aug;8(5):349-58
references.pmid: 18690841
references.citation: Oncologist. 2011;16 Suppl 2:14-22
references.pmid: 21346036